DSM plans higher prices

Gibson, Jane
October 2006
ICIS Chemical Business;10/30/2006, Vol. 1 Issue 41, p4
Trade Publication
The article reports on the confidence of DSM that it will be able to push through higher prices in the fourth quarter of 2006 and meet its target of a 6-8% increase in operating profits for 2006. The company has announced investments in performance products and engineering plastics, and has doubled capacity at its Nanjing, China caprolactam facility. As part of its Vision 2010 innovation boost, DSM intends to spend 15% of capex on business development, including an aggressive acquision strategy.


Related Articles

  • New polyamide 6 plant in North America.  // Chemical Fibers International;Aug2014, Vol. 64 Issue 3, p132 

    The article reports on the plan of Heerlen, Netherlands-based life science and performance materials company Koninklijke DSM NV in a polymerization plant in North America in 2014.

  • Contract Services' Crystal Ball. Miller, Jim // BioPharm International;Feb2003, Vol. 16 Issue 2, p22 

    Reports developments in the pharmaceutical industry as of February 2003 in the U.S. Acquisition of Magellan Laboratories by Cardinal Health; Use of electronic data capture in the clinical trials of Novartis; Plans inspection conducted by Food and Drug Administration for DSM Pharmaceuticals Inc.

  • COMPANY NEWS.  // Adhesives & Sealants Industry;Mar2010, Vol. 17 Issue 3, p7 

    The article offers information on several updates on companies related to the sealants and adhesives industry in the U.S. Down and Guild Inc. will now distribute Clariant Corp.'s biocides product line in 11 states west of the Rocky Mountains. The Mapei Corp. had acquired the ceramic tile...

  • Untitled.  // Chemical Week;7/23/2003, Vol. 165 Issue 26, p35 

    Presents news briefs on the pharmaceuticals and chemical industry, as of July 2003. Agreement signed by DSM Biologics with biotechnology firm Pharming in Leiden, the Netherlands; Acquisition made by specialty sugars producer Chicago, Illinois-based ZuChem.

  • DSM Gets Another Concession in Roche Buy.  // Chemical Market Reporter;8/4/2003, Vol. 264 Issue 3, p5 

    Reports that DSM Pharmaceutical Inc. has negotiated another reduction in the price it is paying to takeover Roche Pharmaceutical's vitamin and fine chemicals division in Europe.

  • Collaborations: DSM Biologics and Crucell Announce Licensing Deal with LFB Biotechnologies.  // Pharmaceutical Technology;Sep2007, Vol. 31 Issue 9, p134 

    The article reports that DSM Biologics of New Jersey and the biotechnology company Crucell NV of the Netherlands has signed a nonexclusive research licensing agreement with LFB Biotechnologies of Paris, France. It is stated that the LFB will use the PER.C6 production technology of Crucell to...

  • Western Producers Under Pressure from China. Scott, Alex // Chemical Week;3/24/2004, Vol. 166 Issue 10, p22 

    Focuses on the pressure given by Chinese manufacturers of antibiotics to Western manufacturers by decreasing prices. Domination of Chinese producers over Western producers in the market; Comparison of prices of antibiotics in 1994, 2003 and 2004; Joint ventures formed by DSM with Chinese...

  • Make Deals or Die. Kawakami, Sumie // J@pan Inc.;Apr2003, Issue 42, p14 

    Assesses the state of the buyout market in Japan as of April 1, 2003. Funds that have entered the market; Action to be taken by the acquired company for buyout investments to gain profits; Stand of the Japanese government on buyout activities. INSET: MKS PARTNERS.

  • Innovations.  // ICIS Chemical Business;1/15/2007, Vol. 2 Issue 49, p30 

    This section presents two international news briefs related to the chemical industry. A license agreement was signed by DSM Biologics and Dutch biotechnology partner Crucell with Portuguese biotechnology company Biotecnol and its U.S. subsidiary. Fluoropolymer producer Dyneon has bought...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics